Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Biogen    BIIB

BIOGEN (BIIB)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/14/2018 09/17/2018 09/18/2018 09/19/2018 09/20/2018 Date
338.68(c) 334.4(c) 336.89(c) 338.91(c) 341.24 Last
881 972 944 135 1 243 594 844 809 499 232 Volume
-0.56% -1.26% +0.74% +0.60% +0.69% Change
More quotes
Financials (USD)
Sales 2018 13 187 M
EBIT 2018 6 787 M
Net income 2018 4 601 M
Finance 2018 815 M
Yield 2018 -
Sales 2019 13 589 M
EBIT 2019 7 271 M
Net income 2019 5 070 M
Finance 2019 4 690 M
Yield 2019 -
P/E ratio 2018 15,32
P/E ratio 2019 13,60
EV / Sales2018 5,12x
EV / Sales2019 4,68x
Capitalization 68 271 M
More Financials
Company
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases.It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment... 
Sector
Pharmaceuticals
Calendar
10/24Earnings Release
More about the company
Surperformance© ratings of Biogen
Trading Rating : Investor Rating :
More Ratings
Latest news on BIOGEN
05:28pNICE wavers on end of life exception for DLBCL CAR Ts, says Kymriah doesn't m..
AQ
09/10CF TRUST : U.K. health secretary backs NHS in Vertex stalemate
AQ
09/07BIOGEN : to Present at the Morgan Stanley 16th Annual Global Healthcare Conferen..
AQ
09/06BIOGEN : Enrolls First Patient in Global Phase 3 Study of BIIB093 for Large Hemi..
AQ
09/05BIOGEN : Enrolls First Patient in Global Phase 3 Study of BIIB093 (IV Glibenclam..
AQ
09/05BIOGEN : Enrolls First Patient in Global Phase 3 Study of BIIB093 (IV Glibenclam..
AQ
09/04BIOGEN : Enrolls First Patient in Global Phase 3 Study of BIIB093 (IV Glibenclam..
AQ
08/29BIOGEN : and Eisai Report Data from Long-Term Extension Phase 1b Study of Invest..
AQ
08/28BIOGEN : and Eisai Report Data from Long-Term Extension Phase 1b Study of Invest..
AQ
08/16BIOGEN : Findings from Biogen Yields New Data on Gene Therapy (Identification of..
AQ
More news
Sector news : Biopharmaceuticals
07:35pAnimal health firm Elanco surges 41 percent on debut
RE
06:55pWALL STREET STOCK EXCHANGE : Aurora Cannabis plans U.S. stock listing in October
RE
05:55pELI LILLY AND : Lilly Spinoff Elanco Animal Health Surges Early in Market Debut ..
DJ
02:44pONCOMED PHARMACEUTICALS : Says Celgene Won't Exercise Option to License Navicixi..
DJ
02:36pPFIZER : 20vPnC Vaccine Gets FDA Breakthrough-Therapy Designation
DJ
More sector news : Biopharmaceuticals
MarketScreener Strategies on BIOGEN 
BIOGEN - 02/26
Close to an important medium term support level
BUY
BIOGEN IDEC  - 2014
Back on a stimulating support
BUY
More Strategies
Latest Tweets
02:26pGet the latest news and updates for $WTBA $GILD $BIIB $TLAB $KEYN automatical.. 
09/18$BIIB Biogen to Report Third Quarter 2018 Financial Results October 23, 2018 .. 
09/18Oppenheimer Raises Biogen Q3 2018 Earnings Estimates to $6.61 EPS (Previously.. 
09/14Analysts Anticipate Biogen Inc $BIIB Will Announce Earnings of $6.80 Per Shar.. 
09/14$BIIB Biogen Inc. - June 2018 (LTM): Peer Snapshot: Compares key performance.. 
More tweets
Qtime:169
News from SeekingAlpha
11:15aEquillium Begins U.S. IPO Effort 
09/19GameStop's Fundamentals Are Declining - Cramer's Lightning Round (9/18/18) 
09/12Biogen, Inc. (BIIB) Presents at Morgan Stanley 16th Annual Global Healthcare .. 
09/11HQL : A Top-Notch Biotech CEF 
09/10PHARMACEUTICAL/BIOPHARMA SEPTEMBER M : Vanishing Uncertainty 
Chart BIOGEN
Duration : Period :
Biogen Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOGEN
Short TermMid-TermLong Term
TrendsBearishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 389 $
Spread / Average Target 15%
EPS Revisions
Managers
NameTitle
Michel Vounatsos Chief Executive Officer & Director
Stelios B. Papadopoulos Chairman
Jeffrey D. Capello Chief Financial Officer & Executive Vice President
Alfred W. Sandrock Chief Medical Officer & Executive Vice President
Michael D. Ehlers Executive VP-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
BIOGEN6.38%68 271
CSL LIMITED43.31%66 162
ALEXION PHARMACEUTICALS1.99%27 182
GRIFOLS0.63%17 763
BIOMARIN PHARMACEUTICAL11.65%17 718
CELLTRION HEALTHCARE CO LTD--.--%11 959